23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ARCUTIS BIOTHERAPEUTICS INC. › 2023-2024

ARCUTIS BIOTHERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ARCUTIS BIOTHERAPEUTICS INC.’s Form 8-K, filed June 18, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 162Asset managers, any item
  • 895Fund votes
  • June 14, 2024Meeting date

Results at a glance

Meeting of June 14, 2024: 5 items on ARCUTIS BIOTHERAPEUTICS INC.’s Form 8-K, filed June 18, 2024: 5 passed (calculated).

Dissent

Significant dissent: 1 director (29.2% against); 1 say-on-pay vote (68.1% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Rubric Capital (13F, 6.7%, as of September 30, 2026)

Explore ARCUTIS BIOTHERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ARCUTIS BIOTHERAPEUTICS INC.

These tallies are ARCUTIS BIOTHERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARCUTIS BIOTHERAPEUTICS INC. — official shareholder meeting results, meeting held June 14, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Terrie Curran 77,210,679---- 6,467,28012,428,038 92%Passed (calculated)—
Elect Director: Halley Gilbert 75,828,706---- 7,849,25312,428,038 91%Passed (calculated)—
Elect Director: Keith R. Leonard, Jr. 59,273,804---- 24,404,15512,428,038 71%Passed (calculated)—
2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 95,949,9636,661149,373 ---- 99.9%Passed (calculated)—
3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers 56,906,21526,716,60255,142 --12,428,038 68%Passed (calculated)—

Source: ARCUTIS BIOTHERAPEUTICS INC., Form 8-K, filed with the SEC on June 18, 2024 — read the filing on EDGAR.

How asset managers voted at the ARCUTIS BIOTHERAPEUTICS INC. 2023-2024 meeting

162 asset managers disclosed a vote on at least one ARCUTIS BIOTHERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Halley Gilbert

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 75,828,706WITHHELD: 7,849,253
Details: description as filed, official tally, votes by 49 asset managers

Description as filed by funds: Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Halley E. Gilbert

ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Halley Gilbert”): 75,828,706 for, 7,849,253 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 20,486,006 for, 5,985,660 withheld.

FORWITHHOLD
FOR: 20,486,006WITHHOLD: 5,985,660
Largest asset managers voting on “Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their succ” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Prudential/PGIM6,221,0170 00For
State Street13,9650 05,646,093Withhold
Vanguard5,008,2360 00For
BlackRock2,105,3050 00For
FRANKLIN STRATEGIC SERIES1,525,5450 00For
American Century967,8950 00For
Charles Schwab751,9060 00For
Direxion Shares ETF Trust636,4000 00For
JPMorgan527,1900 00For
Fidelity311,2280 044,277Mixed
AMG FUNDS310,9810 00For
T. Rowe Price278,2210 00For
TIAA239,4970 00For
John Hancock238,6550 00For
Federated Hermes237,2360 00For
Equitable124,8000 074,700Mixed
Lincoln Financial125,9110 063,100Mixed
Aberdeen148,8740 00For
ProShares141,0670 00For
Voya00 0136,893Withhold
SEI124,6100 00For
Invesco96,7340 00For
AIG/SunAmerica75,6790 00For
QUANTITATIVE MASTER SERIES LLC50,0430 00For
Global X35,8160 00For

Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).

Elect Director: Keith R. Leonard, Jr.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%WITHHELD
FOR: 59,273,804WITHHELD: 24,404,155
Details: description as filed, official tally, votes by 49 asset managers

Description as filed by funds: Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Keith R. Leonard, Jr.

ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Keith R. Leonard, Jr.”): 59,273,804 for, 24,404,155 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 12,952,748 for, 13,518,918 withheld.

FORWITHHOLD
FOR: 12,952,748WITHHOLD: 13,518,918
Largest asset managers voting on “Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their succ” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Prudential/PGIM6,221,0170 00For
State Street5,652,0860 07,972For
Vanguard00 05,008,236Withhold
BlackRock00 02,105,305Withhold
FRANKLIN STRATEGIC SERIES00 01,525,545Withhold
American Century00 0967,895Withhold
Charles Schwab00 0751,906Withhold
Direxion Shares ETF Trust00 0636,400Withhold
JPMorgan00 0527,190Withhold
Fidelity00 0355,505Withhold
AMG FUNDS310,9810 00For
T. Rowe Price00 0278,221Withhold
TIAA239,4970 00For
John Hancock198,7110 039,944Mixed
Federated Hermes00 0237,236Withhold
Equitable00 0199,500Withhold
Lincoln Financial63,1000 0125,911Mixed
Aberdeen00 0148,874Withhold
ProShares00 0141,067Withhold
Voya136,8930 00For
SEI00 0124,610Withhold
Invesco96,7340 00For
AIG/SunAmerica00 075,679Withhold
QUANTITATIVE MASTER SERIES LLC00 050,043Withhold
Global X00 035,816Withhold

Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).

Elect Director: Terrie Curran

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 77,210,679WITHHELD: 6,467,280
Details: description as filed, official tally, votes by 49 asset managers

Description as filed by funds: Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Terrie Curran

ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Terrie Curran”): 77,210,679 for, 6,467,280 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 23,980,412 for, 2,491,254 withheld.

FOR
FOR: 23,980,412WITHHOLD: 2,491,254
Largest asset managers voting on “Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their succ” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Prudential/PGIM6,221,0170 00For
State Street5,652,0860 07,972For
Vanguard5,008,2360 00For
BlackRock2,105,3050 00For
FRANKLIN STRATEGIC SERIES1,525,5450 00For
American Century00 0967,895Withhold
Charles Schwab751,9060 00For
Direxion Shares ETF Trust00 0636,400Withhold
JPMorgan527,1900 00For
Fidelity311,2280 044,277Mixed
AMG FUNDS310,9810 00For
T. Rowe Price278,2210 00For
TIAA239,4970 00For
John Hancock208,0110 030,644Mixed
Federated Hermes237,2360 00For
Equitable124,8000 074,700Mixed
Lincoln Financial151,6350 037,376Mixed
Aberdeen00 0148,874Withhold
ProShares00 0141,067Withhold
Voya00 0136,893Withhold
SEI124,6100 00For
Invesco00 096,734Withhold
AIG/SunAmerica00 075,679Withhold
QUANTITATIVE MASTER SERIES LLC50,0430 00For
Global X35,8160 00For

Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).

Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 11 wordings of this item as funds reported it.

68% Majority: yes · of votes cast

FOR 68%AGAINST
FOR: 56,906,215AGAINST: 26,716,602

Prior year: 85.6% for (June 2, 2023 meeting) ▼ 17.6 pts

Details: description as filed, official tally, votes by 162 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers”): 56,906,215 for, 26,716,602 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 49 asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Prudential/PGIM6,221,0170 00For
State Street5,652,0867,972 00For
Vanguard05,008,236 00Against
BlackRock02,105,305 00Against
FRANKLIN STRATEGIC SERIES01,525,545 00Against
American Century0967,895 00Against
Charles Schwab0751,906 00Against
Direxion Shares ETF Trust0636,400 00Against
JPMorgan0527,190 00Against
Fidelity0355,505 00Against
AMG FUNDS0310,981 00Against
T. Rowe Price0278,221 00Against
TIAA0239,497 00Against
John Hancock0238,655 00Against
Federated Hermes0237,236 00Against
Equitable0199,500 00Against
Lincoln Financial63,100125,911 00Mixed
Aberdeen0148,874 00Against
ProShares0141,067 00Against
Voya0136,893 00Against
SEI0124,610 00Against
Invesco096,734 00Against
AIG/SunAmerica075,679 00Against
QUANTITATIVE MASTER SERIES LLC050,043 00Against
Global X035,816 00Against

Fund voting reports, all 49 managers: 11,946,584 for, 14,525,082 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 127 asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JENNISON ASSOCIATES LLC10,610,81425,911 00For
SUVRETTA CAPITAL MANAGEMENT, LLC7,361,2850 00For
Polar Capital Holdings Plc6,821,7160 00For
State Street6,767,00513,540 00For
Rubric Capital Management LP5,312,5030 00For
FRANKLIN ADVISERS INC04,432,314 00Against
Cormorant Asset Management, LP2,238,2180 00For
BlackRock34,2091,721,109 00Against
Bain Capital Life Sciences Investors, LLC1,532,2370 00For
GW&K Investment Management, LLC8,2291,348,299 00Against
FARALLON CAPITAL MANAGEMENT LLC01,185,577 00Against
JPMorgan01,063,474 00Against
American Century0999,185 00Against
Citadel778,9810 00For
J. Goldman & Co LP772,1860 00For
Charles Schwab0751,906 00Against
PERCEPTIVE ADVISORS LLC736,3260 00For
Prudential/PGIM710,0008,775 00For
Rafferty Asset Management, LLC0636,400 00Against
BALYASNY ASSET MANAGEMENT L.P.0627,676 00Against
HSBC0559,330 00Against
EcoR1 Capital, LLC500,0000 00For
Northern Trust400,229898 00For
T. Rowe Price0401,006 00Against
Eversept Partners, LP371,3470 00For

Institutional-manager reports, all 127 managers: 45,295,593 for, 18,157,815 against, 130 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 95,949,963AGAINST: 6,661

Prior year: 99.3% for (June 2, 2023 meeting) ▲ 0.6 pts

Details: description as filed, official tally, votes by 49 asset managers

Description as filed by funds: TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS, OF ERNST & YOUNG LLP, AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 95,949,963 for, 6,661 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 26,471,666 for.

FOR
FOR: 26,471,666
Largest asset managers voting on “TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS, OF ERNST & YOUNG LLP, AS ” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Prudential/PGIM6,221,0170 00For
State Street5,660,0580 00For
Vanguard5,008,2360 00For
BlackRock2,105,3050 00For
FRANKLIN STRATEGIC SERIES1,525,5450 00For
American Century967,8950 00For
Charles Schwab751,9060 00For
Direxion Shares ETF Trust636,4000 00For
JPMorgan527,1900 00For
Fidelity355,5050 00For
AMG FUNDS310,9810 00For
T. Rowe Price278,2210 00For
TIAA239,4970 00For
John Hancock238,6550 00For
Federated Hermes237,2360 00For
Equitable199,5000 00For
Lincoln Financial189,0110 00For
Aberdeen148,8740 00For
ProShares141,0670 00For
Voya136,8930 00For
SEI124,6100 00For
Invesco96,7340 00For
AIG/SunAmerica75,6790 00For
QUANTITATIVE MASTER SERIES LLC50,0430 00For
Global X35,8160 00For

Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).

Largest ARCUTIS BIOTHERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 115,505,437 shares outstanding at the time of that meeting.

Fund voting reports: top ARCUTIS BIOTHERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2023-2024
#Asset manager % of shares outstanding
1Prudential/PGIM 5.39%
2State Street 4.90%
3Vanguard 4.34%
4BlackRock 1.82%
5FRANKLIN STRATEGIC SERIES 1.32%
6American Century 0.84%
7Charles Schwab 0.65%
8Direxion Shares ETF Trust 0.55%
9JPMorgan 0.46%
10Fidelity 0.31%
Institutional-manager reports: top ARCUTIS BIOTHERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2023-2024
#Asset manager % of shares outstanding
1JENNISON ASSOCIATES LLC 9.21%
2SUVRETTA CAPITAL MANAGEMENT, LLC 6.37%
3Polar Capital Holdings Plc 5.91%
4State Street 5.87%
5Rubric Capital Management LP 4.60%
6FRANKLIN ADVISERS INC 3.84%
7Cormorant Asset Management, LP 1.94%
8BlackRock 1.52%
9Bain Capital Life Sciences Investors, LLC 1.33%
10GW&K Investment Management, LLC 1.17%

Reported ARCUTIS BIOTHERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ARCUTIS BIOTHERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Jennison Associates LLC12,128,533 10.50%Proxy statement (DEF 14A), proxy filed April 26, 2024
Prudential Financial, Inc.9,884,137 8.56%Proxy statement (DEF 14A), proxy filed April 26, 2024
S9,534,837 8.25%Schedule 13G, filed February 13, 2024
Suvretta Capital Management, LLC9,534,837 8.25%Proxy statement (DEF 14A), proxy filed April 26, 2024
Patrick J. Heron8,789,596 7.61%Proxy statement (DEF 14A), proxy filed April 26, 2024
Frazier Life Sciences VIII, L.P.8,785,284 7.61%Schedule 13D, filed March 6, 2024
State Street8,784,038 7.60%Form 13F, quarter ended March 31, 2024
BlackRock8,573,995 7.42%Form 13F, quarter ended March 31, 2024
Vanguard Group7,146,090 6.19%Form 13F, quarter ended March 31, 2024
Ruberic Capital Management6,644,530 5.75%Proxy statement (DEF 14A), proxy filed April 26, 2024

Percentages above are of 115,505,437 shares outstanding, as reported by ARCUTIS BIOTHERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ARCUTIS BIOTHERAPEUTICS INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 162 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 895 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — FOR was 68% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ARCUTIS BIOTHERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARCUTIS BIOTHERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ARCUTIS BIOTHERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ARCUTIS BIOTHERAPEUTICS (ARQT) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/arcutis-biotherapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.